Table 2.
Patient outcomes by total number of SACT received in the metastatic setting.
| Line of Metastatic SACT | 1st | 2nd | 3rd | 4th | 5th |
|---|---|---|---|---|---|
| Number of Patients | 114 | 78 | 40 | 15 | 6 |
| Best response for each line of SACT n (%) | CR 4 (3) | CR 1 (1) | CR 0 (0) | CR 0 (0) | CR 0 (0) |
| PR 46 (40) | PR 13 (17) | PR 3 (8) | PR 1 (7) | PR 0 (0) | |
| SD 26 (23) | SD 20 (26) | SD 9 (23) | SD 2 (13) | SD 2 (33) | |
| PD 36 (32) | PD 40 (51) | PD 28 (70) | PD 11 (73) | PD 4 (67) | |
| NA 2 (2) | NA 4 (5) | NA 0 (0) | NA 1 (7) | NA 0 (0) | |
| Regimen modification n (%) | 43 (38) | 17 (22) | 4 (10) | 3(20) | 0 |
| Median PFS for each line of SAC.T (95% CI), months | 6.9 | 5.0 | 2.0 | 3.9 | 2.7 |
| (5.8–9.4) | (3.4–6.1) | (1.7–3.8) | (1.7–5.4) | (1.5–NA) | |
| Median OS (95% C.I) for patients whose total lines of SACT in metastatic setting was: (months) | 9.0 | 14.9 | 18.7 | 31.7 | 32.0 |
| (4.1–27.7) | (9.6–19.0) | (14.3–28.6) | (20.246.5) | (N/A) |
Legend: SACT: systemic anticancer therapy, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NA: not applicable. PFS: progression-free survival, OS: overall survival.